Recently, the highly anticipated finals of the "2026 Xiong'an International Medical and Healthcare Technology Application Competition" concluded successfully at the Xiong'an New Area Future City Scenario Creation Science and Technology Innovation Park. Laviana Pharma, with its independently developed "AI Process Chemistry Large Model" project, stood out among numerous top-tier medical innovation achievements and successfully won the third prize in the competition.

Themed "Digital and Intelligent Healthcare, Healthy Future," this competition was hosted by the Xiong'an Future City Scenario Creation Organizing Committee and co-organized by the Hebei Provincial Health Commission, among other units. The competition attracted 514 participating units from home and abroad, collecting a total of 666 projects covering 13 countries and regions. After rigorous selection through preliminary review and qualifiers, 173 high-quality projects with leading technology, mature models, and great potential for clinical translation advanced to the finals.

At the finals site, the Laviana Pharma team comprehensively showcased the disruptive innovation and broad application prospects of the "AI Process Chemistry Large Model" in the field of process chemistry through a format of "live presentation + expert Q&A." The finalist projects focused on cutting-edge directions such as brain science, AI-assisted diagnosis, high-end medical imaging, intelligent rehabilitation, and the modernization of traditional Chinese medicine, presenting numerous achievements with independent intellectual property rights and high translation potential.

The "AI Process Chemistry Large Model" breaks through traditional experience barriers, positioning artificial intelligence as a "global optimizer," while human experts focus on validation and implementation, forming an efficient human-machine collaborative closed loop. The model innovatively integrates engineering tools such as safety assessment and supply chain analysis, filling a domestic gap in related fields, and supports seamless translation from laboratory to industrialization, potentially reducing physical experiments by over 60%. After applying this model, the new drug R&D cycle is expected to be shortened by 30% to 50%, comprehensive costs reduced by approximately 50%, and the success rate of industrial implementation increased by over 85%. This will significantly enhance R&D efficiency, allowing more patients to access life-saving drugs faster, so that lives are no longer lost due to long waits.

This large model breaks through traditional experience barriers, positioning AI as a "global optimizer," while human experts focus on validation and implementation, forming an efficient human-machine collaborative closed loop. The model innovatively integrates engineering tools such as safety assessment and supply chain analysis, filling a domestic gap in the field of AI process chemistry, and supports seamless translation from laboratory to industrialization, potentially reducing physical experiments by over 60%. After applying this model, the new drug R&D cycle is expected to be shortened by 30% to 50%, comprehensive costs reduced by approximately 50%, and the success rate of industrial implementation increased by over 85%. This will significantly enhance R&D efficiency, allowing more patients to access life-saving drugs faster, so that lives are no longer lost due to long waits.

Adhering to the concept of "competing, connecting, and implementing simultaneously," this competition is committed to building a complete closed loop for translation: "competition—exhibition—negotiation—production." This award for Laviana Pharma is not only an authoritative recognition of its technological innovation capabilities but also lays the foundation for further promoting the deep integration of AI technology with the medical and healthcare industry and accelerating the transformation of outstanding medical scientific achievements. In the future, Laviana Pharma will continue to increase investment in scientific research, deepen the application of AI and automation technologies in drug R&D, and provide more efficient and intelligent one-stop CDMO services for global innovative pharmaceutical companies.